Skip to Navigation Skip to Search Skip to Content
Search All Centers

ASH 2018 Coverage: A Scientist Shares Insight on Drug Development

Read Transcript Download/Print Transcript

Published on December 17, 2018

As part of our coverage of the 2018 American Society of Hematology (ASH) Annual Meeting, Dr. Phillip Liu, Senior Director at Incyte Corporation, joined Patient Power to discuss the discovery of fuxolitinib (Jakafi). Dr. Liu shares the story of when the JAK2V617F mutation was identified and what later trials revealed. Tune in now to hear the back story of this groundbreaking treatment option for MPNs.

Featuring

You might also like

Transcript | ASH 2018 Coverage: A Scientist Shares Insight on Drug Development

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

So we started to investigate. So I remember exactly when he came back from the meeting and announced this finding in the room.  We were all filled with excitement but at the same time we looked around in puzzlement because none of us had ever heard of these diseases before, polycythemia vera or myelofibrosis, and that was really the beginning.  

 

Remember, knowledge can be the best medicine of all.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.